PO-256 The extracorporeal immunopharmacotherapy (EIPHT) and remote results of cervical cancer and ovarian cancer treatment

Abstract

IntroductionThe aim of this study was to investigate the effect of extracorporeal immunopharmacotherapy on long-term results of treatment of cervical cancer and ovarian cancer.Material and methodsThe study included patients with cervical cancer and ovarian cancer T2–3N0–1M0 stages, w All the patients with ovarian cancer in a combined therapy of adjuvant or neoadjuvant mode comprising combination chemotherapy of cisplatin 75mg/m2+Cyclophosphan 1000mg/m2 for 4 days at 4–6 courses 1 every 3 weeks and surgical treatment within the scope of radical surgery. EIPHT was performed by exfusion of 500–1000 ml of autoblood in ’Gemakon’ or ’Terumo’ sterile containers and its centrifugation at 3000 rpm for 30 min. Then the obtained leukotrombomass and erythrocytic mass were incubated with thymalin in a total dose of 30 mg (for 3 procedures) at 37° C for 60–100 min, with the subsequent return of the conjugate to the circulatory system of patients. In total, patients received 2 sessions of extracorporeal therapy at the beginning of admission to hospital and before discharge from the hospital.Results and discussionsDepending on the type of EIPHT being performed, 4 groups of patients with cervical cancer and OC were isolated. The 1 st group (34 patients) included patients with cervical cancer and OC who did not receive immunotherapy. In 2nd (32 patients) cervical cancer and 42 patients with OC, immunotherapy in the form of subcutaneous injections of thymomimetics (thymalin) in standard doses for 10–14 days was performed. The 3-rd group included 28 patients with cervical cancer and 36 patients with OC, who underwent EIPHT, and group 4 comprised 45 patients with cervical cancer and 47 patients with OC used EIPHT in combination with plasmapharesis. The conducted studies led to the conclusion that the greatest effectiveness in reducing side effects of chemotherapy in the complex treatment of patients with cervical cancer and stage II-III stage II, as well as in improving the subjective state of patients and their quality of life, has an immunotherapy scheme that includes intermittent plasmapheresis with subsequent EIPHT, which reduces the main clinical manifestations of toxicity of chemotherapy, improves the indicators of the subjective state of patients and the quality of their life.ConclusionThe use of EIPHT methods in the complex therapy of oncogynecologic diseases makes it possible to increase the parameters of the five-year total and disease-free survival of patients with cervical cancer and ovarian cancer.